WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H531947
CAS#: 143692-48-2 (HCl)
Description: GYKI53655 Hydrochloride is a non-competitive AMPA and kainate receptor antagonist. GYKI53655 Hydrochloride exhibits anticonvulsant activity. GYKI53655 Hydrochloride also blocks GluK3 homomeric receptors (IC50 = 63 μM) and GluK2b(R)/GluK3 heteroreceptors (IC50 = 32 μM) at high concentrations.
Hodoodo Cat#: H531947
Name: GYKI53655 Hydrochloride
CAS#: 143692-48-2 (HCl)
Chemical Formula: C19H21ClN4O3
Exact Mass: 0.00
Molecular Weight: 388.850
Elemental Analysis: C, 58.69; H, 5.44; Cl, 9.12; N, 14.41; O, 12.34
Related CAS #: 143692-18-6 (Free Base) 143692-48-2 (HCl)
Synonym: GYKI53655 Hydrochloride; GYKI53655 HCl; GYKI53655; GYKI 53655; GYKI-53655.
IUPAC/Chemical Name: 1-(4-Aminophenyl)-3-methylcarbamyl-4-methyl-3,4-dihydro-7,8-methylenedioxy-5H-2,3-benzodiazepine hydrochloride
InChi Key: ASLCSBBDVWPSQT-UHFFFAOYSA-N
InChi Code: InChI=1S/C19H20N4O3.ClH/c1-11-7-13-8-16-17(26-10-25-16)9-15(13)18(22-23(11)19(24)21-2)12-3-5-14(20)6-4-12;/h3-6,8-9,11H,7,10,20H2,1-2H3,(H,21,24);1H
SMILES Code: CC1N(C(NC)=O)N=C(C2=CC=C(N)C=C2)C3=CC4=C(OCO4)C=C3C1.[H]Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 388.85 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Miyazaki S, Minami T, Mizuma H, Kanazawa M, Doi H, Matsumura S, Lu J, Onoe H, Furuta K, Suzuki M, Ito S. The action site of the synthetic kainoid (2S,3R,4R)-3-carboxymethyl-4-(4-methylphenylthio)pyrrolidine-2-carboxylic acid (PSPA-4), an analogue of Japanese mushroom poison acromelic acid, for allodynia (tactile pain). Eur J Pharmacol. 2013 Jun 15;710(1-3):120-7. doi: 10.1016/j.ejphar.2012.10.023. PubMed PMID: 23124023.
2: Alt A, Weiss B, Ornstein PL, Gleason SD, Bleakman D, Stratford RE Jr, Witkin JM. Anxiolytic-like effects through a GLUK5 kainate receptor mechanism. Neuropharmacology. 2007 Jun;52(7):1482-7. PubMed PMID: 17418283.
3: Rodríguez-Moreno A, Sihra TS. Presynaptic kainate receptor-mediated facilitation of glutamate release involves Ca2+-calmodulin and PKA in cerebrocortical synaptosomes. FEBS Lett. 2013 Mar 18;587(6):788-92. doi: 10.1016/j.febslet.2013.01.071. PubMed PMID: 23416300.
